Gardasil efficacious against HPV 16 infection
Studies of GARDASIL, Merck’s Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference – In a study of an extended follow up of 290 women na?ve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.